A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01515306
First received: January 18, 2012
Last updated: April 9, 2014
Last verified: April 2014

January 18, 2012
April 9, 2014
July 2012
March 2013   (final data collection date for primary outcome measure)
  • Part A: Pharmacokinetics - area under the concentration versus time curve (AUC) of paclitaxel [ Time Frame: Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Part A: Pharmacokinetics - maximum observed drug concentration (Cmax) of paclitaxel [ Time Frame: Cycle 1: 0,1, 2, 5, 7, 24, 48, 72 and 168 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Part A: Pharmacokinetics - area under the concentration versus time curve (AUC) of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Part A: Pharmacokinetics - maximum observed drug concentration (Cmax) of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Part B: Pharmacokinetics - area under the concentration versus time curve (AUC) of ramucirumab as monotherapy [ Time Frame: Cycle 1: 0,1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, 336, 408, and 504 hours post ramucirumab infusion ] [ Designated as safety issue: No ]
  • Pharmacokinetics: area under the concentration versus time curve (AUC) of paclitaxel [ Time Frame: Cycle 1: 0,1, 1.5, 2, 5, 8, 24, 48, 72 and 168 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum observed drug concentration (Cmax) of paclitaxel [ Time Frame: Cycle 1: 0,1, 2, 5, 8, 24, 48, 72 and 168 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Pharmacokinetics: area under the concentration versus time curve (AUC) of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 2, 5, 8, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum observed drug concentration (Cmax) of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 2, 5, 8, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01515306 on ClinicalTrials.gov Archive Site
  • Part A: Pharmacokinetics - area under the concentration versus time curve (AUC) of ramucirumab in the presence of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Part A: Pharmacokinetics - maximum observed drug concentration (Cmax) of ramucirumab in the presence of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 1.5, 2, 5, 7, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Parts A: Immunogenicity of ramucirumab in combination with paclitaxel - Incidence of anti-Ramucirumab antibodies [ Time Frame: Day 1 of Cycle 2, and 30 days after last dose of study drug ] [ Designated as safety issue: Yes ]
  • Parts B: Immunogenicity of ramucirumab ramucirumab as monotherapy - Incidence of anti-Ramucirumab antibodies [ Time Frame: Day 1 of Cycle 2, and 30 days after last dose of study drug ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: area under the concentration versus time curve (AUC) of ramucirumab in the presence of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 2, 5, 8, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum observed drug concentration (Cmax) of ramucirumab in the presence of paclitaxel [ Time Frame: Cycle 2: -1, 0, 1, 2, 5, 8, 24, 48, 72, 96, 168, 264, 336 hours post paclitaxel infusion ] [ Designated as safety issue: No ]
  • Incidence of anti-Ramucirumab antibodies [ Time Frame: Day 1 of Cycle 2, and 30 days after last dose of study drug ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors.

Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Malignant Solid Tumor
  • Biological: ramucirumab (IMC-1121B)
    ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
    Other Name: LY3009806
  • Drug: paclitaxel
    paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
  • Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel

    Cycle 1: paclitaxel administered on Day 1 of 2-week cycle.

    Cycle 2: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.

    Cycle 3 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of each 4-week cycle.

    Interventions:
    • Biological: ramucirumab (IMC-1121B)
    • Drug: paclitaxel
  • Experimental: Part B: ramucirumab (IMC-1121B) and paclitaxel

    Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.

    Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.

    *After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A.

    Interventions:
    • Biological: ramucirumab (IMC-1121B)
    • Drug: paclitaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
September 2014
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has histologic or cytologic documentation of a malignant solid tumor
  • Has an advanced solid tumor that is refractory to standard therapy or for which no standard therapy is available
  • Part A only: Has had 0-1 prior taxane-containing treatment regimens (including taxane monotherapy), which must have been completed at least 6 months before the first dose of study medication (prior bevacizumab is allowed)
  • Part B only: Prior bevacizumab- and taxane-containing treatment regimens (including taxane monotherapy) are allowed, provided these regimens have been completed at least 6 months before the first dose of study medication
  • Has resolution to Grade ≤ 1 of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy, which must not have exceeded Grade 1, by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0)
  • Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
  • Has adequate hematologic function. Blood transfusion is allowed but must be completed 48 hours before study drug administration
  • Has adequate hepatic function (bilirubin ≤ 1.5 times the upper limit of normal [ULN], aspartate transaminase [AST] and alanine transaminase [ALT] ≤ 1.5 x ULN
  • Has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN, the calculated creatinine clearance (CrCl) should be ≥ 40 milliliter/minute (mL/min)
  • Urinary protein is <2+ on dipstick or routine urinalysis (UA)
  • Must have adequate coagulation function as defined by an international normalized ratio (INR) of ≤ 1.5 and a partial thromboplastin time (PTT) or an activated PTT (aPTT) ≤ 1.5 x ULN
  • Eligible participants of reproductive potential agree to use adequate method of contraception during the study period and for 12 weeks after the last dose of study medication

Exclusion Criteria:

  • Is receiving concomitant therapy with clinically relevant inhibitors or inducers of cytochrome P450, CYP2C8, CYP3AY and/or isoenzymes
  • Are currently enrolled in, or discontinued within the last 14 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Has received a monoclonal antibody within 42 days prior to first dose of study medication
  • Has received radiotherapy within 14 days prior to first dose of study medication
  • Has received cytotoxic chemotherapy within 21 days (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study medication
  • Has a cardiac left ventricular ejection fraction (LVEF) not within institutional limits of normal on a multigated acquisition scan (MUGA) or echocardiogram
  • Is receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, targeted or other investigational anticancer therapy
  • Is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents. Aspirin use at doses up to 325 milligrams/day (mg/day) and analgesic agents with no or low bleeding risk are permitted
  • Has a history of uncontrolled hereditary or acquired bleeding or thromboembolic disorders
  • Has experienced any arterial thromboembolic event, including myocardial infarction (MI), unstable angina stroke or transient ischemic attack (TIA), within 6 months prior to first dose of study medication
  • Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to first dose of study medication
  • Has experienced a Grade 3 or 4 hemorrhagic event within 3 months prior to first dose of study medication
  • Has experienced peripheral neuropathy ≥ Grade 2 at any time prior to study entry
  • Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
  • History of gastrointestinal perforation and / or fistulae within 6 months prior to randomization
  • Has an ongoing or active infection requiring treatment with intravenous antibiotics
  • Has a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to first dose of study medication
  • Has uncontrolled hypertension
  • Has symptomatic congestive heart failure
  • Has known brain or leptomeningeal disease
  • Has known positive status for human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome-related illness
  • Has known active drug or alcohol abuse that would affect participant's ability to comply with study treatment
  • Has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
  • Has had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study medication
  • Has an elective or planned major surgery during the course of the trial
  • If a primary cancer is non-small-cell lung cancer (NSCLC), participant has intratumor cavitation, radiologically documented evidence of major blood vessel invasion or encasement by cancer, or proximity of cancer to major airways
  • Has received prior ramucirumab (IMC-1121B) therapy
  • The participant has:

    • cirrhosis at a level of Child-Pugh B (or worse)
    • cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01515306
14432, I4T-IE-JVCA, CP12-1032
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP